Fisher & Paykel Healthcare Corporation Limited
FPH.NZ · NZE
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2023 FY | 1.48B | 881.22M | 316.47M | 233.18M | 0.43 |
| 2024 FY | 1.61B | 971.56M | 338.04M | 121.57M | 0.23 |
| 2025 FY | 1.87B | 1.18B | 471.54M | 349.03M | 0.59 |
| 2026 FY | 2.34B | 1.50B | 667.00M | 468.50M | 0.80 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2023 FY | 2.20B | 451.10M | 121.00M | 145.80M | 1.75B |
| 2024 FY | 2.28B | 522.60M | 82.00M | 189.10M | 1.76B |
| 2025 FY | 2.36B | 611.07M | 244.74M | 141.85M | 1.75B |
| 2026 FY | 2.85B | 738.20M | 461.10M | 146.10M | 2.12B |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2023 FY | 238.20M | -211.30M | 26.90M | -195.70M | 32.20M |
| 2024 FY | 429.60M | -339.00M | 90.60M | -145.50M | -35.90M |
| 2025 FY | 507.63M | -68.10M | 439.52M | -181.27M | 165.91M |
| 2026 FY | 663.20M | -172.80M | 490.40M | -252.30M | 196.60M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2023 FY | 15.41B | 15.43B | — | — | — |
| 2024 FY | 15.23B | 15.34B | — | — | — |
| 2025 FY | 19.64B | 19.54B | — | — | — |
| 2026 FY | 21.95B | 21.63B | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q2 | 860.84M | 532.77M | 197.38M | 138.65M | 0.24 |
| 2025 Q4 | 989.90M | 631.25M | 269.73M | 207.27M | 0.35 |
| 2026 Q2 | 1.10B | 697.80M | 298.20M | 213.00M | 0.36 |
| 2026 Q4 | 1.24B | 802.90M | 368.80M | 255.50M | 0.44 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q2 | 2.20B | 457.57M | 105.52M | 136.56M | 1.75B |
| 2025 Q4 | 2.36B | 611.07M | 244.74M | 141.85M | 1.75B |
| 2026 Q2 | 2.63B | 645.10M | 300.00M | 148.20M | 1.99B |
| 2026 Q4 | 2.85B | 738.20M | 461.10M | 146.10M | 2.12B |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q2 | 210.87M | -35.84M | 175.03M | -79.19M | 34.60M |
| 2025 Q4 | 292.03M | -31.46M | 260.57M | -100.30M | 147.90M |
| 2026 Q2 | 245.80M | -52.00M | 193.80M | -140.70M | 35.50M |
| 2026 Q4 | 417.40M | -120.80M | 296.60M | -111.60M | 161.10M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q2 | 20.48B | 20.51B | — | — | — |
| 2025 Q4 | 19.64B | 19.54B | — | — | — |
| 2026 Q2 | 21.73B | 21.58B | — | — | — |
| 2026 Q4 | 21.95B | 21.63B | — | — | — |